Ankylosing SpondylitisSPACTIVENCT01845818
Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
An observational study of Ankylosing Spondylitis and Psoriatic Arthritis, run by AbbVie.
Trial summary
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment. Changes in the employment status and work productivity of participants with AS and PsA before and after the start of adalimumab will be noted. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Ankylosing Spondylitis, Psoriatic Arthritis
- How many people
- 183 participants
- Where
- No sites listed yet
- Study dates
- 5 Jun 2013to 23 Jun 2017
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: Participants with AS and PsA followed in university or peripheral hospitals or peripheral private practices with experience in AS and PsA care.
Who may be able to join
- Patient >= 18 years and <= 50 years
- Patient diagnosed with AS or PsA
- Patient to be initiated on adalimumab (according to the Marketing Authorization and Belgian reimbursement criteria)
- Patient willing to sign informed consent
Who cannot join
- Any contraindication for adalimumab as specified in the corresponding Summary of Product Characteristics (SmPC)
- Patient previously treated with biologics
- Patient participating in other AbbVie-sponsored trials
About this study
Official title: Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
Changes in the employment status and work productivity of participants with AS and PsA before and after the start of adalimumab will be noted. The relationship between employment status, work productivity, disease activity and clinical evaluations will be evaluated. Since AS and PsA might be diseases with a strong impact on the daily life of the participant, an evaluation will be performed to the effect of the disease on quality of life and work productivity.
- Conditions
- Ankylosing Spondylitis, Psoriatic Arthritis
- Keywords
- work productivity, multicenter study
- Medical subject headings
- Spondylitis, Ankylosing, Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ankylosing Spondylitis and Psoriatic Arthritis | Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Combined)
The mean percentage of TWPI due to disease (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which disease decreased productivity (%)* [number of hours worked / (number of hours of work missed due to disease + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. "Change" was calculated as the value at baseline minus the value at Month 18.
Measured: Baseline, Month 18
Secondary outcomes (16)
Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Separately)
The mean percentage of TWPI due to disease (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which disease decreased productivity (%)* [number of hours worked / (number of hours of work missed due to disease + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. "Change" was calculated as the value at baseline minus the value at Month 18.
Measured: Baseline, Month 18
Number of Participants Employed at Each Assessed Visit
As assessed by the WPAI questionnaire, a questionnaire used to evaluate lost work productivity due to disease (yes=employed; no=not employed). Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Percentage of Missed Working Hours (Absenteeism) Due to Disease 7 Days Prior to Each Visit
Absenteeism, presented as the mean percentage of work time missed due to disease (as reported on the WPAI), and calculated as: 100*number of hours of work missed due to disease / (number of hours of work missed due to disease + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Percentage of Activity Impairment Due to Disease During the 7 Days Prior to Each Visit
Activity impairment due to disease (the extent to which disease affected the ability to perform usual daily activities, as reported on the WPAI) is presented as the mean percentage of activity impairment, calculated as 100*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Percentage of Impairment While Working Due to Disease (Presenteeism) 7 Days Prior to Each Visit
As measured by the WPAI-Specific Health Problem questionnaire. Presenteeism (the extent to which disease decreased productivity, as reported on the WPAI) is presented as the mean percentage of impairment while working due to disease, and calculated as: 100*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time (Psoriatic Arthritis)
The HAQ-DI is a self-reported assessment of how the participant's disease affects their ability to function in their daily life over the past week. The HAQ-DI for a participant is calculated as the mean of the following 8 category scores: dressing and grooming, rising, eating, walking, hygiene, reach, grip, and activities. Scores range from 0 to 3, with a lower score demonstrating less disability. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Dermatology Life Quality Index (DLQI) Scores Over Time (Psoriatic Arthritis)
The DLQI score is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which the participant's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much (score of 3), a lot, a little, or not at all (score of 0); responses are summed. The DLQI score ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Health Assessment Questionnaire Modified for Spondyloarthropathies (HAQ-S) Scores Over Time (Ankylosing Spondylitis)
The HAQ-S is a self-reported measure to assess the physical function and health-related quality of life. The Disability Index (DI) of HAQ-S is calculated as the mean of the following 8 category scores (range: 0 [without any difficulty] to 3 [unable to do]): Dressing and Grooming, Rising, Eating, Walking, Hygiene, Reach, Grip, and Activities. Five additional items in the functional status measure were included in the HAQ-S, including carrying heavy packages, sitting for long periods, able to work at a flat topped table, and (if the participant had a driver's license or a car) able to look in the rear view mirror and able to turn head to drive in reverse. The overall score ranges from 0 (no disability) to 3 (very severe, high-dependency disability). Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Disease Activity Score 28 (DAS-28) Over Time (Psoriatic Arthritis)
The DAS-28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and the Subject's Global Assessment of Disease Activity (subject rates disease activity using a Likert scale from 0 [low activity] to 10 [high activity]) are included in the DAS-28 score. Scores on the DAS-28 range from 0 to 10. A DAS-28 score > 5.1 indicates high disease activity, a DAS-28 score < 3.2 indicates low disease activity, and a DAS-28 score < 2.6 indicates clinical remission. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Percentage of Body Surface Area (BSA) Affected Over Time (Psoriatic Arthritis)
Percentage of BSA affected by psoriatic arthritis was assessed by clinical evaluation. Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Over Time (Ankylosing Spondylitis)
The BASDAI is used for measuring and evaluating disease activity in ankylosing spondylitis. This index consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (or enthesitis, defined as inflammation of tendons and ligaments), duration of morning stiffness, severity of morning stiffness. A visual analogue scale ranging from 0 (none) to 10 (very severe) is used to answer the questions. The final BASDAI score averages the individual assessments for a final score range of 0 to 10 (0 being no problem and 10 being the worst problem). Last observation is the last observation after baseline at which any of the questionnaire items was completed.
Measured: Baseline, Months 3, 6, 12, 18
Acute Phase Reactant: Erythrocyte Sedimentation Rate (ESR) Values Over Time
The ESR is a practicable and sensitive but not specific parameter for measuring disease progression. By means of the ESR it can be generally distinguished between an active and nonactive rheumatic disease. The normal reference range is, as a rule, 0 to 10 mm/h for men and 0 to 15 mm/h for women. The higher the ESR value out of the normal range, the higher is the disease activity. Last observation is the last observation after baseline at which an assessment was completed.
Measured: Baseline, Months 3, 6, 12, 18
Acute Phase Reactant: C-Reactive Protein (CRP) Values Over Time
CRP is an acute phase reactant plasma protein, normally produced by the liver, which is commonly used as an indirect measure of the extent and activity of an inflammation. The CRP normal reference range in the blood is, as a rule, from 0 to 1.0 mg/dL. Last observation is the last observation after baseline at which an assessment was completed.
Measured: Baseline, Months 3, 6, 12, 18
Physician's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time
The VAS score assessed by physicians was used to determine the disease activity of ankylosing spondylitis and psoriatic arthritis in the past week. The level of disease activity was measured in millimeters (mm) on a 100 mm horizontal line. The score ranged from 0 (none) to 100 (most disease activity).
Measured: Baseline, Months 3, 6, 12, 18
Participant's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time
The VAS score assessed by participants was used to determine the disease activity of ankylosing spondylitis and psoriatic arthritis in the past week. The level of disease activity was measured in millimeters (mm) on a 100 mm horizontal line. The score ranged from 0 (none) to 100 (most disease activity).
Measured: Baseline, Months 3, 6, 12, 18
Participant's Global Assessment of Pain VAS Scores Over Time
The VAS score assessed by participants was used to determine the pain due to ankylosing spondylitis and psoriatic arthritis in the past week. The level of pain was measured in millimeters (mm) on a 100 mm horizontal line. The score ranged from 0 (no pain) to 100 (severe pain).
Measured: Baseline, Months 3, 6, 12, 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2013 (estimated)
- Study start5 Jun 2013
- Primary completion23 Jun 2017
- Study completion23 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Ankylosing SpondylitisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 183 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01845818
- Sponsor's protocol ID
- P13-990
- Acronym
- SPACTIVE
- Status last verified
- May 2018
- First submitted
- 1 May 2013
- Last updated
- 9 Jan 2019
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium
- ClinicalTrials.gov ID
- NCT01845818
- Acronym / sponsor ID
- SPACTIVE / P13-990
- Conditions
- Ankylosing Spondylitis, Psoriatic Arthritis
- Keywords
- work productivity, multicenter study
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 183 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 5 Jun 2013 (actual)
- Primary completion
- 23 Jun 2017 (actual)
- Study completion
- 23 Jun 2017 (actual)
- First posted
- 3 May 2013 (estimated)
- Results
- Posted 9 Jan 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study will document to what extent in daily clinical practice the work productivity is affected before and after the start of adalimumab treatment.
Changes in the employment status and work productivity of participants with AS and PsA before and after the start of adalimumab will be noted. The relationship between employment status, work productivity, disease activity and clinical evaluations will be evaluated. Since AS and PsA might be diseases with a strong impact on the daily life of the participant, an evaluation will be performed to the effect of the disease on quality of life and work productivity.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ankylosing Spondylitis and Psoriatic Arthritis | – | –Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Participants with AS and PsA followed in university or peripheral hospitals or peripheral private practices with experience in AS and PsA care.
Key inclusion criteria (4 listed)
- Patient >= 18 years and <= 50 years
- Patient diagnosed with AS or PsA
- Patient to be initiated on adalimumab (according to the Marketing Authorization and Belgian reimbursement criteria)
- Patient willing to sign informed consent
Key exclusion criteria (3 listed)
- Any contraindication for adalimumab as specified in the corresponding Summary of Product Characteristics (SmPC)
- Patient previously treated with biologics
- Patient participating in other AbbVie-sponsored trials
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Combined)
Time frame: Baseline, Month 18
The mean percentage of TWPI due to disease (based on the WPAI questionnaire) is presented, calculated as: Absenteeism (%) + extent to which disease decreased productivity (%)* [number of hours worked / (number of hours of work missed due to disease + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. "Change" was calculated as the value at baseline minus the value at Month 18.
16 secondary outcomes
Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Separately)
Time frame: Baseline, Month 18
Number of Participants Employed at Each Assessed Visit
Time frame: Baseline, Months 3, 6, 12, 18
Percentage of Missed Working Hours (Absenteeism) Due to Disease 7 Days Prior to Each Visit
Time frame: Baseline, Months 3, 6, 12, 18
Percentage of Activity Impairment Due to Disease During the 7 Days Prior to Each Visit
Time frame: Baseline, Months 3, 6, 12, 18
Percentage of Impairment While Working Due to Disease (Presenteeism) 7 Days Prior to Each Visit
Time frame: Baseline, Months 3, 6, 12, 18
Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time (Psoriatic Arthritis)
Time frame: Baseline, Months 3, 6, 12, 18
Dermatology Life Quality Index (DLQI) Scores Over Time (Psoriatic Arthritis)
Time frame: Baseline, Months 3, 6, 12, 18
Health Assessment Questionnaire Modified for Spondyloarthropathies (HAQ-S) Scores Over Time (Ankylosing Spondylitis)
Time frame: Baseline, Months 3, 6, 12, 18
Disease Activity Score 28 (DAS-28) Over Time (Psoriatic Arthritis)
Time frame: Baseline, Months 3, 6, 12, 18
Percentage of Body Surface Area (BSA) Affected Over Time (Psoriatic Arthritis)
Time frame: Baseline, Months 3, 6, 12, 18
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Over Time (Ankylosing Spondylitis)
Time frame: Baseline, Months 3, 6, 12, 18
Acute Phase Reactant: Erythrocyte Sedimentation Rate (ESR) Values Over Time
Time frame: Baseline, Months 3, 6, 12, 18
Acute Phase Reactant: C-Reactive Protein (CRP) Values Over Time
Time frame: Baseline, Months 3, 6, 12, 18
Physician's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time
Time frame: Baseline, Months 3, 6, 12, 18
Participant's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time
Time frame: Baseline, Months 3, 6, 12, 18
Participant's Global Assessment of Pain VAS Scores Over Time
Time frame: Baseline, Months 3, 6, 12, 18
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Ankylosing Spondylitis
RecruitingPhase 1
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Psoriasis, Ankylosing Spondylitis
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Identification of Serum Level of Glutathione Peroxidase 4
Spondyloarthropathy
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
Questions about this trial
What is this clinical trial studying?
An observational study of Ankylosing Spondylitis and Psoriatic Arthritis, run by AbbVie.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jan 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Combined) (time frame: Baseline, Month 18). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2019.